Novartis' Ribociclib (Kisqali (R)) receives high AGO Level of Recommendation for endocrine Therapy in premenopausal Women with HER2-metastatic Breast Cancer

首页> 外文期刊>Breast care >Novartis' Ribociclib (Kisqali (R)) receives high AGO Level of Recommendation for endocrine Therapy in premenopausal Women with HER2-metastatic Breast Cancer

【24h】

Novartis' Ribociclib (Kisqali (R)) receives high AGO Level of Recommendation for endocrine Therapy in premenopausal Women with HER2-metastatic Breast Cancer

机译：Novartis'ribociclib（Kisqali（r））获得高前期内分泌治疗的高前期妇女患有Her2-转移乳腺癌的建议水平

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Breast care》 |2021年第3期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿生殖器肿瘤;
关键词

相似文献

外文文献
中文文献
专利

1. Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer [J] . Li Bian, Feng-Rui Xu, Ze-Fei Jiang 中华医学杂志（英文版） . 2020,第019期
2. Breast-conserving surgery and combined therapy for women breast cancer： a report of 216 cases [J] . Xianju, Qin, Junxue, 中德临床肿瘤学杂志：英文版 . 2007,第003期
3. Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer [J] . Le-Sang Shen, Xiao-Yan Jin, Xu-Meng Wang, 中华医学杂志（英文版） . 2020,第009期
4. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) [J] . Nadia Harbeck, Fabio Franke, Rafael Villanueva-Vazquez, Therapeutic advances in medical oncology. . 2020,第12期

机译：与核遗传物阳性阳性患者的健康有关的生活质量，HER2阴性晚期乳腺癌加上内分泌治疗：III期随机临床试验的结果（Monaleesa-7）
5. A phase 2 randomized, double-blind, placebo-controlled study of ribociclib or placebo in combination with endocrine therapy for the treatment of premenopausal and postmenopausal Chinese women with HR+, HER2-, advanced breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：第2期随机，双盲，安慰剂对照研究与安慰剂与内分泌治疗组合治疗患有HR +，Her2-，晚期乳腺癌
6. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial [J] . Tripathy Debu, Im Seock-Ah, Colleoni Marco, The lancet oncology . 2018,第7期

机译：Ribociclib加上患有激素受体阳性，晚期乳腺癌（Monaleesa-7）的前进妇女的内分泌治疗：随机阶段3试验
7. ROLE OF ENDOCRINE DISRUPTOR CHEMICALS ON THE TISSUE LEVELS OF AHR AND SEX STEROID RECEPTORS IN PREMENOPAUSAL BREAST CANCER PATIENTS : COMPARISON WITH BENIGN FEMALE TUMOURS [C] . Sepideh Arbabi Bidgoli International Conference on Endocrine Disruptors . 2012

机译：内分泌干扰化学品对前肢乳腺癌患者AHR和性类固醇受体组织水平的作用：与良性女性肿瘤的比较
8. Adherence to Adjuvant Endocrine Therapy among Women Diagnosed with Early Breast Cancer. [D] . Farias, Albert. 2015

机译：在诊断为早期乳腺癌的女性中坚持辅助内分泌治疗。
9. Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women [O] . Eunae Jeong, Changjun Wang, Leslie Wilson, 2021

机译：将ribociclib添加到内分泌治疗的成本效果为Her-阳性海洋病女性女性患者的Her2阴性晚期乳腺癌患者
10. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer [O] . Yoon‐Sim Yap, Joanne Chiu, Yoshinori Ito, 2020

机译：Ribociclib，CDK 4/6抑制剂，加上亚洲女性的内分泌治疗，具有晚期乳腺癌
11. Changes in Ovarian Stromal Function and Associated Symptoms in Premenopausal Women Undergoing Chemotherapy for Breast Cancer [R] . Frost, M. H. 2008

机译：绝经前妇女乳腺癌卵巢基质功能及相关症状的变化

Novartis' Ribociclib (Kisqali (R)) receives high AGO Level of Recommendation for endocrine Therapy in premenopausal Women with HER2-metastatic Breast Cancer

著录项

相似文献

相关主题

期刊订阅